Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year.  Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year.  For the year ended December 31, 2012, Isis had an NOL of $60.4 million compared to $61.3 million for 2011.  Isis added a substantial amount of cash to its balance sheet throughout 2012, ending the year with nearly $375 million.  On a GAAP basis, Isis reported a loss from operations of $26.1 million and $68.9 million for the three and twelve months ended December 31, 2012, respectively, compared to $18.6 million and $71.1 million for the same periods in 2011. 

"Last month the FDA approved KYNAMRO™.  KYNAMRO is the first systemic antisense drug to be sold commercially.  This is an important event for patients with homozygous familial hypercholesterolemia, for Isis, and for our antisense technology.  KYNAMRO's approval for chronic use in patients who have a severe and fatal disease highlights the potential of our technology to create drugs that could provide benefit for patients," said B. Lynne Parshall, chief operating officer of Isis.  "In addition to KYNAMRO, we have a number of promising new drugs that will report later-stage clinical data this year, setting us up for an exciting year of pipeline activity."

"2012 was a strong year for Isis.  We begin 2013 in a significantly improved financial position with nearly $375 million in cash.  Since the beginning of 2013, we have already received a $25 million milestone payment from Genzyme and a $7.5 million milestone payment from GSK.  With the commercial launch of KYNAMRO and a maturing pipeline of drugs, we have many
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
6. Kewaunee Scientific Reports Improved Results for Third Quarter
7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
8. Questcor Reports Fourth Quarter and Full Year 2012 Results
9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... schizophrenia twice as likely to have children with the ... News) -- Parents of children with autism have double ... condition than parents of children without autism, according to ... the information may provide a way for experts to ...
... its Kind in the U.S. to Address Epidemic Drug & Alcohol Use, by Suburban Teens; Integrates Academics, Intervention, ... Hope; Teens to Share Personal Stories, MENDHAM, N.J., May 5 , WHAT: ... next ... nation,s only fully-licensed coeducational special ed ...
... Club Members Share Life-Changing Experiences, SAN RAMON, ... largest,national fitness club chain, today launched an innovative ... overcome personal challenges,through fitness. The "12 Million Lives" ... a life-changing journey by using the power of ...
... announced plans to,align their Ophthalmic Strategic Business Unit (Lumenis ... the highest standards of,quality and reliability., Lumenis, Ophthalmic ... who will lead the unit for the present time ... for Business Development, and,will replace Mr. Jake Vander Zanden, ...
... enrolling in the state childrens health insurance program (SCHIP) ... would further prolong these childrens need to address asthma ... which happens when patients switch to SCHIP when they ... waiting periods to qualify for SCHIP. Waiting periods ...
... LABAs ARE SAFE AND EFFECTIVE FOR COPD , ... (LABA) to increased risk for adverse events or respiratory-related ... obstructive pulmonary disease (COPD); however, a recent article shows ... metaanalysis, researchers from Spain, Argentina, and Uruguay reviewed the ...
Cached Medicine News:Health News:Autistic Kids More Likely to Have Parents With Mental Illness 2Health News:Daytop - NJ to Dedicate New Preparatory School This Week 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 2Health News:24 Hour Fitness Gets Personal in Groundbreaking New Brand Campaign 3Health News:Lumenis Announces changes in Lumenis Vision Strategic Business Unit 2Health News:New SCHIP enrollees have unmet health care needs 2Health News:News briefs: May issue of the journal Chest 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: